The FDA is likely to order label changes on breast cancer drug tamoxifen after a study showed that using the medicine simultaneously with certain antidepressants, including Paxil, Prozac and Zoloft, increases the risk of breast cancer recurrence, an agency official said. In the clinical trial, women who took both treatments for at least a year had a disease recurrence rate of 16%, compared with 7.5% for those not on the drugs.

Related Summaries